Wang and co-workers observed that treatment with myricetin reduced iron content and inhibited transferrin receptor 1 (TfR1) in human neuroblastoma cells, and significantly reversed scopolamine-induced cognitive deficits in a mouse model of Alzheimer’s disease [180]. Here, TFRC is linked to Alzheimer disease.